NASH Drugs

Selected news for the healthcare topic - NASH Drugs, collected since 4/2019. We are still establishing shared news links for this healthcare topic.

Please provide a valid email address.
Shares Healthcare News With (link):
Other Healthcare Entities

Selected Headines

Date Headline (link) Source Relevant Snippet
1/5/2021 Terns raises $87M to advance trials of NASH drugs MedCity News Startups , Pharma Terns raises $87M to advance trials of NASH drugs The startup, which licensed three NASH candidates from Eli Lilly, raised $87 million from the drugmaker and Deerfield Management. Post a comment / Jan 5, 2021 at 3:14 PM Shares 0After gaining a big backer in Eli Lilly & Co. two years ago, Terns Pharmaceuticals now has two NASH candidates in clinical trials. The startup, headquartered in Foster City, Calif ...
10/27/2020 Pfizer Q3 cull sees midstage fast-tracked NASH drug axed, with a cancer vaccine and arthritis asset also chopped FierceBiotech ... and auditing. Watch On-Demand No reason was given for its cull, except that it was filed under “discontinued projects.” It still appears to be active in combo trials, likely the future of many NASH drugs, most of which have seen major setbacks and flops over the past few years. RELATED: Trial flops see Pfizer cut GlycoMimetics pact, Merck ax KalVista research deal The second midstage cull affected arthritis asset ...
9/22/2020 CureApp: could digital therapeutics be a lifeline for NASH patients? nridigital.com ... patients as Intercept’s NDA for OCA was the first for this indication. However, unfortunately, this is not the only recent bad news in the field of NASH. Two other companies, Gilead and Genfit, had NASH drugs fail in late stage clinical trials. At the end of 2019, Gilead announced its two therapies – firsocostat and cilofexor – failed in a Phase II trial both alone and in combination to reduce scarring in ...
9/2/2020 Intercept Pharmaceuticals Is Cutting Staff as NASH Dream Fades barrons.com ... areas of development for big pharma and biotech alike, have suffered a string of disappointments in recent months. In July, Genfit (ticker: GNFT), which had been expected to bring out one of the first NASH drugs, said it was dropping its NASH program altogether. Now, Intercept says it is scaling back its staff due to the Food and Drug Administration’s decision in June to reject its application for approval of ...
8/19/2020 ALBO Drops NASH Drug Development, FDA Says No To Filgotinib, SUPN On Watch, Vanda & ODYSSEY rttnews.com Today's Daily Dose brings you news about another headstone in the graveyard of NASH drugs, ADC Therapeutics' near-term catalysts, Gilead's Filgotinib being turned down by the FDA, Sorrento terminating its CFO, Supernus' regulatory catalyst for November, and Vanda's progress in COVID-19 treatment Tradipitant. Read on… 1. Albireo Discontinues NASH Drug Development Albireo Pharma Inc. ( ALBO ) has decided not to pursue the development of its drug candidate Elobixibat in ...
8/12/2020 Genfit diagnostic pivot offers bright spot after major drug flop FierceBiotech Genfit knew early on that a quick, easy test for nonalcoholic steatohepatitis would be key to the success of NASH drugs—including its own, elafibranor. Although it canned the NASH program last month after a phase 3 flop, the French biotech is plugging away at its blood-based diagnostic, which could hit the market as early as the second half of 2020. The test, dubbed NIS4, considers four blood-based ...
7/23/2020 A Top Contender in the Race for a NASH Drug Drops Out barrons.com ... Drug Administration had said that the benefit of its proposed NASH treatment didn’t outweigh the potential risks. Now, the French biotech Genfit (ticker: GNFT), which had been expected to bring one of the first NASH drugs to the market, said it is getting out of the race altogether. In a statement Wednesday evening , Genfit (ticker: GNFT) said it was ending a Phase 3 clinical trial of its drug elafibranor in ...
7/23/2020 French biotech Genfit shifts gears after Phase III NASH failure MedCity News A company that had been potentially second in line to receive Food and Drug Administration approval for a drug to treat nonalcoholic steatohepatitis is now moving away from developing NASH drugs after the failure of a Phase III clinical trial. Lille, France-based Genfit said Wednesday it had formally terminated the Phase III RESOLVE-IT trial of elafibranor in patients with NASH and fibrosis. Instead, it will prioritize the drug’s ...
7/15/2020 Non-Alcoholic Steatohepatitis (NASH) Drugs Market 2020-2029 Globe Newswire ... under development and growth in e-commerce pharmaceutical products sales. The global non-alcoholic steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs. The current NASH drugs market is wholly occupied by off-label drugs as there are no clinically approved medicines for the treatment of NASH. However, certain therapeutic drugs, from large pharmaceutical drugs, are expected to enter the market ...
7/14/2020 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market: Insights & Forecast with Potential Impact of COVID-19 (2020-2029) - ResearchAndMarkets.com | Business & Finance | heraldchronicle.com Business Wire ... under development and growth in e-commerce pharmaceutical products sales. The global non-alcoholic steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs. The current NASH drugs market is wholly occupied by off-label drugs as there are no clinically approved medicines for the treatment of NASH. However, certain therapeutic drugs, from large pharmaceutical drugs, are expected to enter the market ...
7/7/2020 COVID-19 Outbreak-Global Nash Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 reportsnreports.com COVID-19 Outbreak-Global Nash Drugs Industry Market Report-Development Trends, Threats, Opportunities and Competitive Landscape in 2020 3660 7320 Table of Contents Non-alcoholic Steatohepatitis or NASH is a common term for silent liver disease and can result into cirrhosis, in which liver is permanently damaged and after a certain point could lead to death. The Nash Drugs market revenue was xx.xx Million USD in 2019, and will reach ...
6/29/2020 Intercept Stock Off - FDA Declines to Clear Liver-Disease Drug TheStreet ... by the buildup of fat in the liver and can result in liver failure, cancer and death. The disease affects around 25% of Americans and Reuters reported that some analysts expect the market for NASH drugs to reach up to $35 billion as obesity rates climb. “We are disappointed to see the determination the agency has reached based on an apparently incomplete review and without having provided medical experts and ...
6/29/2020 FDA turns down Intercept's long-anticipated NASH drug MedCity News ... FDA’s decision, CEO Mark Pruzanski said the company will meet with the FDA to discuss the CRL, but added that the company is “very concerned” that the agency’s “still evolving expectations” will make bringing NASH drugs to market exceedingly challenging. “At no point during the review did the FDA communicate that OCA was not approvable on an accelerated basis, and we strongly believe that the totality of data submitted to ...
6/29/2020 U.S. FDA declines to approve first drug for obesity-linked liver disease | News | WIN 98.5 wincountry.com ... Americans and is poised to become the leading cause of liver transplants. As fat-filled diets make bigger chunks of the global population prone to developing the disease, some analysts expect the market for NASH drugs to reach up to $35 billion. However, the industry has been littered with disappointments, including last year's trial failure of Gilead Sciences Inc's three-drug combination. Intercept's therapy has previously received the FDA's accelerated ...
6/29/2020 U.S. FDA declines to approve first drug for obesity-linked liver disease dailymagazine.news ... Americans and is poised to become the leading cause of liver transplants. As fat-filled diets make bigger chunks of the global population prone to developing the disease, some analysts expect the market for NASH drugs to reach up to $35 billion. However, the industry has been littered with disappointments, including last year's trial failure of Gilead Sciences Inc's three-drug combination. Intercept's therapy has previously received the FDA's accelerated ...
5/14/2020 After Drug Failure, Genfit's Cupboard Is Nearly Bare gurufocus.com ... The company said it would work with regulators to determine the next steps regarding continuation of the trial, according to an article in Feedspot. Genfit’s elafibranor was one of the two most highly touted NASH drugs. Now moving to the head of the pack is Intercept’s obeticholic acid, which is expected to be reviewed by the U.S. Food and Drug Administration next month. NASH has proved to be a huge ...
2/4/2020 Study Validating Echosens FibroScan FAST Score for Cost-Effective, Efficient Identification of People at Risk for Active Fibrotic NASH Published in Lancet Gastroenterology & Hepatology BioSpace ... timely and significant because the efficient identification of active fibrotic NASH has long been a challenge for drug companies, with many now developing drugs that target this health crisis. “In clinical trials to develop NASH drugs, over 50% of patients fail to meet the inclusion criteria, with the majority not having active fibrotic-NASH,” continues Harrison. “As treatments become available for active fibrotic NASH, FibroScan and tools like FAST support ...
12/20/2019 Will we see the world's first approved NASH drug in 2020? FierceBiotech ... entirely convinced in clinical trials, with Intercept’s drug dogged by a troublesome side effect profile and Genfit’s rival failing a phase 2 study. The data could deter physicians and payers from backing the first NASH drugs, potentially limiting use to the sickest NASH patients. Webinar How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC CROs are often at the forefront of adopting new technologies to make ...
12/10/2019 Why do we need a NASH drug? NASH leaders weigh in FierceBiotech ... liver inflammation and even reverse liver scarring. RELATED: Special Report — 8 programs to watch in NASH: Four letters and a multibillion-dollar opportunity So, why is everyone piling into NASH? Leaders at companies developing NASH drugs pointed to patients whose fatty liver has led to scarring that can’t be reversed with weight loss. “First off, weight loss via diet and exercise is difficult to achieve and difficult to maintain in ...
10/30/2019 Global Non-Alcoholic Steatohepatitis (NASH) Drugs Market 2019-2028 with Profiles of Bristol Myers Squibb, Gilead Sciences, Allergan, Intercept Pharma, Galmed Pharma and Genfit Globe Newswire ... under development and growth in E-Commerce pharmaceutical products sales. The global Non-Alcoholic Steatohepatitis (NASH) drugs market has two major segments, based on drug classes - Off-Label drugs and Therapeutic Drugs. The current NASH drugs market is wholly occupied by off-label drugs as there are no clinically approved medicines for the treatment of NASH. However, certain therapeutic drugs, from large pharmaceutical drugs, are expected to enter the market ...